Edesa stock slumps 30% amid skin rash drug’s mixed phase 2b trial results

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


Edesa Biotech (NASDAQ:EDSA) stock fell ~33% on Tuesday after the corporate reported information from a phase 2b trial of skin dysfunction remedy EB01

The firm is exploring EB01 as a monotherapy for moderate-to-severe continual Allergic Contact Dermatitis (ACD) — an itchy rash brought on

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!